secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0000950170-25-085588
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon shareholders approve increase in authorized common shares to 300M
------------------------------------------------------------------------

- Shareholders approved increase in authorized common stock from 200M to 300M shares (40.79M for, 0.49M against).
- Approved amendment to extend officer exculpation protection to fullest extent under Delaware law (30.04M for, 1.29M against).
- Elected Class II directors Keith Katkin, Allan Kirk, and John McBride for three-year terms ending 2028.
- Ratified Deloitte & Touche as independent auditor for FY2025 (41.31M for, 36k against).
- Authorized share increase and officer exculpation amendments became effective June 10, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/0000950170-25-085588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017025085588/eldn-20250610.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-085588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer